SC
VRTX icon

Stephens Consulting’s Vertex Pharmaceuticals VRTX Stock Holding History

Stephens Consulting’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7
Closed -$3.12K – 1151
2025
Q2 		$3.12K Buy
+7
New +$3.23K ﹤0.01% 441
2025
Q1 		– Sell
-55
Closed -$22.1K – 1556
2024
Q4 		$22.1K Hold
55
– – 0.01% 266
2024
Q3 		$25.6K Sell
55
-12
-18% -$5.76K 0.01% 242
2024
Q2 		$31.4K Buy
+67
New +$29.1K 0.01% 224
2022
Q4 		– Sell
-132
Closed -$38.2K – 564
2022
Q3 		$38.2K Hold
132
– – 0.03% 193
2022
Q2 		$37.2K Hold
132
– – 0.03% 196
2022
Q1 		$34.4K Sell
132
-161
-55% -$38.2K 0.03% 221
2021
Q4 		$64.3K Buy
+293
New +$57K 0.05% 182

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Stephens Consulting's VRTX Position: Q3 2025 in Review

Stephens Consulting sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 7 shares — an estimated $3.12K sold.

Stephens Consulting first reported a position in VRTX in Q4 2021 and held it in 8 quarters. The position peaked at $64.3K in Q4 2021. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Stephens Consulting reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 7 Vertex Pharmaceuticals shares in Q3 2025, an estimated $3.12K.
  • Stephens Consulting first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Stephens Consulting's Vertex Pharmaceuticals position peaked at $64.3K in Q4 2021.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.